Drug Type Small molecule drug |
Synonyms LY 450108, LY450108 |
Target |
Mechanism AMPA receptor modulators(Glutamate receptor ionotropic AMPA modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H22F2N2O3S |
InChIKeyACOXQYLJOQAHST-ZDUSSCGKSA-N |
CAS Registry376594-67-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Phase 1 | - | - | |
Parkinson Disease | Phase 1 | - | - |
Not Applicable | - | vedcpmlkwv(xvqafrlgdm) = Dizziness was the most frequent adverse event for both LY450108 and LY451395 eiwvypglek (yiidqwaukp ) | Positive | 03 Nov 2002 | |||